SAPIEN 3经导管主动脉瓣置换与外科手术在中危患者中的10年结局
本研究比较中危重度症状性主动脉瓣狭窄患者接受第三代球囊扩张式SAPIEN 3经导管主动脉瓣置换(TAVR)与外科主动脉瓣置换的10年结局。通过倾向性评分匹配后每组783例,10年全因死亡率TAVR组83.4%、外科组82.3%(HR 1.01, 95%CI 0.91-1.13; P=0.82),主动脉瓣再干预率分别为2.0%和1.9%(P=0.47),10年超声心动图平均跨瓣压差分别为11.0 mmHg和12.6 mmHg。结论认为两种策略的长期死亡率、再干预率和血流动力学相似。
要点
- 中危主动脉瓣狭窄患者TAVR与外科手术10年全因死亡率相似(83.4% vs 82.3%)。
- 10年主动脉瓣再干预率低且两组相当(2.0% vs 1.9%)。
- 10年超声心动图平均跨瓣压差两组接近(11.0 vs 12.6 mmHg)。
核心结论
- 中危症状性重度主动脉瓣狭窄患者接受SAPIEN 3 TAVR或外科手术,10年死亡率和再干预率相似,血流动力学相似。
研究设计与样本
- 前瞻性多中心研究,比较PARTNER 2 SAPIEN 3中危注册研究(P2S3i)的TAVR患者与PARTNER 2A随机试验(P2A)的外科患者。
- 共2005例接受瓣膜植入,TAVR 1069例、外科936例;倾向性评分1:1匹配后每组783例。
- 匹配后基线:平均年龄约82岁,女性43%,平均STS评分5.5%。
- 评估10年全因死亡、主动脉瓣再干预及核心实验室判读的超声心动图结局。
主要发现
- 10年全因死亡率TAVR组83.4%、外科组82.3%(HR 1.01, 95%CI 0.91-1.13; P=0.82)。
- 竞争死亡调整后主动脉瓣再干预率TAVR组2.0%、外科组1.9%(P=0.47)。
- 10年时有超声心动图数据的TAVR 32例、外科30例,平均跨瓣压差分别为11.0 mmHg和12.6 mmHg。
临床怎么用
- 对于中危症状性重度主动脉瓣狭窄患者,SAPIEN 3 TAVR可作为外科手术的替代选择,长期结局相似。
- 10年随访中TAVR组再干预率低,但需注意高龄患者竞争死亡风险对长期结局解读的影响。
局限性
- 扩展长期随访存在差异性失访,可能影响结果解读。
- 老年人群竞争死亡风险高,10年超声心动图数据仅少数患者可用。
- TAVR与外科患者来自不同研究(注册研究与随机试验),虽经倾向性评分匹配仍可能存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transcatheter aortic valve replacement (TAVR) is an alternative to surgical aortic valve replacement for patients with symptomatic severe aortic stenosis. However, long-term outcomes data are lacking for TAVR, particularly with newer-generation transcatheter heart valves. OBJECTIVES: The purpose of this study was to compare 10-year outcomes of intermediate-risk patients who underwent TAVR with the third-generation, balloon-expandable SAPIEN 3 valve in the PARTNER 2 SAPIEN 3 Intermediate-risk Registry (P2S3i) with those who underwent surgery in the PARTNER 2A (P2A) randomized trial. METHODS: Intermediate-risk patients were enrolled in the P2A trial from 2011 through 2013 and in the P2S3i registry in 2014. These prospective, multicenter studies used the same eligibility criteria and stratified patients based on suitability for transfemoral or transthoracic (transapical/transaortic) access. Ten-year outcomes were evaluated, including all-cause mortality, aortic valve reintervention, and core laboratory-adjudicated echocardiographic outcomes. Patient reconsent was required at 5 years for extended 10-year follow-up, and vital status sweeps were implemented to improve data completeness for all-cause mortality. To account for potential baseline differences and reduce confounding, P2S3i TAVR patients were propensity score-matched 1:1 to P2A surgical patients. RESULTS: Among 2,005 patients who received a valve, 1,069 underwent TAVR in P2S3i and 936 underwent surgery in P2A. After propensity score matching (N = 783 patients in each group), baseline characteristics were similar between groups: mean age was approximately 82 years, 43% were female, and mean Society of Thoracic Surgeons score was 5.5%. At 10 years, all-cause mortality rate was 83.4% after TAVR and 82.3% after surgery, respectively (HR: 1.01 [95% CI: 0.91-1.13]; P = 0.82). Aortic valve reintervention rates adjusted for competing mortality were 2.0% for TAVR and 1.9% for surgery (P = 0.47). Among 32 TAVR and 30 surgical patients with available echocardiographic data at 10 years, mean gradients were 11.0 mm Hg and 12.6 mm Hg, respectively. CONCLUSIONS: At 10 years, TAVR with the SAPIEN 3 valve and surgery resulted in similar rates of mortality and aortic valve reintervention, and similar hemodynamics in intermediate-risk patients with symptomatic severe aortic stenosis. This analysis highlights challenges associated with extended long-term follow-up of clinical trials, including differential loss to follow-up and the competing risk of mortality in elderly populations. (PARTNER 2A Trial; NCT01314313; PARTNER 2 SAPIEN 3 Intermediate-Risk Registry; NCT03222128).
引用
- Nazif TM, Simonato M, Makkar RR, et al. 10-Year Outcomes of SAPIEN 3 Transcatheter Aortic Valve Replacement or Surgery in Intermediate-Risk Patients. J Am Coll Cardiol. 2026. PMID: 42300820. doi:10.1016/j.jacc.2026.03.170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。